Survival in ovarian cancer patients by histology and family history

References

• Tavassoli F, Devilee P. Tumours of the breast and female genital organs. Pathology and Genetics. IARC, Lyon 2003
   Google Scholar
• Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2006; 20: 339–62
   PubMed Web of Science ®Google Scholar
• Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3–10
   PubMed Web of Science ®Google Scholar
• Cadron I, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I. The management of borderline tumours of the ovary. Curr Opin Oncol 2006; 18: 488–93
   PubMed Web of Science ®Google Scholar
• Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78: 21–7
   PubMedGoogle Scholar
• Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, et al. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol 1989; 34: 88–93
   PubMed Web of Science ®Google Scholar
• Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, et al. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 2003; 13: 776–84
   PubMedGoogle Scholar
• Skirnisdottir I, Seidal T, Karlsson MG, Sorbe B. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 2005; 26: 177–83
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584–9
   PubMed Web of Science ®Google Scholar
• Hemminki K, Sundquist J, Bermejo J. How common is familial cancer? Ann Oncol 2007.
   Google Scholar
• Zweemer RP, Verheijen RH, Gille JJ, van Diest PJ, Pals G, Menko FH. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol 1998; 178: 85–90
   PubMedGoogle Scholar
• Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700–10
   PubMed Web of Science ®Google Scholar
• Hemminki K, Forsti A, Lorenzo Bermejo J. Etiologic impact of known cancer susceptibility genes. Mutat Res 2007.
   Google Scholar
• Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 1999; 59: 868–71
   PubMed Web of Science ®Google Scholar
• Zweemer RP, Verheijen RH, Coebergh JW, Jacobs IJ, van Diest PJ, Gille JJ, et al. Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 2001; 98: 219–23
   PubMedGoogle Scholar
• Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 1998; 16: 397–404
   PubMed Web of Science ®Google Scholar
• Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P. Survival in breast cancer is familial. Breast Cancer Res Treat 2007.
   Google Scholar
• Hemminki K, Granström C, Sundquist J, Lorenzo Bermejo J. The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Hered Cancer Clin Pract 2006; 4: 186–92
   PubMedGoogle Scholar
• SAS Institute. SAS/STAT 9.1 User's Guideed. Cary: SAS Publishing, 2004.
   Google Scholar
• Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003; 101: 885–91
   PubMed Web of Science ®Google Scholar
• Silverberg SG. Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol 1989; 78: 85–109
   PubMedGoogle Scholar
• National Cancer Institute. SEER survival monograph. 2007.
   Google Scholar
• Tohya T. Ovarian sex cord-stromal tumor, unclassified: Case report of endocrinologic findings and review of the literature. Int J Gynecol Cancer 2005; 15: 1153–5
   PubMedGoogle Scholar
• Navarini R, Pineda RL. Malignant mixed mullerian tumors of the ovary. Curr Opin Obstet Gynecol 2006; 18: 20–3
   PubMedGoogle Scholar
• Aparicio J, Germa JR, Garcia del Muro X, Maroto P, Arranz JA, Saenz A, et al. Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005; 23: 8717–23
   PubMed Web of Science ®Google Scholar